当前位置: X-MOL 学术J. Inherit. Metab. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Safety and efficacy of (+)‐epicatechin in subjects with Friedreich's ataxia: A phase II, open‐label, prospective study
Journal of Inherited Metabolic Disease ( IF 4.2 ) Pub Date : 2020-07-16 , DOI: 10.1002/jimd.12285
Muhammad Yasir Qureshi 1, 2 , Marc C Patterson 1, 3 , Vicki Clark 4 , Jonathan N Johnson 1, 2 , Margaret A Moutvic 5 , Sherilyn W Driscoll 5 , Jennifer L Kemppainen 6 , John Huston 7 , Jeff R Anderson 8 , Andrew D Badley 9, 10 , Peter J Tebben 11 , Philip Wackel 1, 2 , Devin Oglesbee 12 , James Glockner 7 , George Schreiner 13 , Sundeep Dugar 13 , Jillienne C Touchette 14 , Ralitza H Gavrilova 3, 6
Affiliation  

(+)‐Epicatechin (EPI) induces mitochondrial biogenesis and antioxidant metabolism in muscle fibers and neurons. We aimed to evaluate safety and efficacy of (+)‐EPI in pediatric subjects with Friedreich's ataxia (FRDA).

中文翻译:

(+)-表儿茶素在弗里德赖希共济失调患者中的安全性和有效性:一项 II 期、开放标签、前瞻性研究

(+)-表儿茶素 (EPI) 诱导肌纤维和神经元中的线粒体生物发生和抗氧化代谢。我们旨在评估 (+)-EPI 在患有弗里德赖希共济失调 (FRDA) 的儿科受试者中的安全性和有效性。
更新日期:2020-07-16
down
wechat
bug